Professor of Hematology
University of Galway, Galway, Ireland
Galway, Ireland
Michael O’Dwyer is a graduate of the University of Galway, Ireland. After initial training in internal medicine and hematology he completed a hematology/oncology fellowship at Oregon Health & Sciences University, Portland, Oregon, USA. He was closely involved in the early development of Imatinib Mesylate, the first kinase inhibitor approved for treatment of cancer, before shifting his focus to multiple myeloma. In 2012 he established a translational research program at University of Galway and since then his research has focused on 4 major areas: (1) how aberrant glycosylation can influence cellular adhesion, trafficking and immune evasion in multiple myeloma (2) the role of the immune microenvironment in multiple myeloma and development of new therapeutic approaches (3) clinical trials in multiple myeloma and (4) use and modification of NK cells as cell therapy for cancer. He established Blood Cancer Network Ireland and was its first Director. In 2015 he founded ONK Therapeutics, which is developing allogeneic NK cell therapy for cancer. He has approximately 120 publications listed on Pub Med with an h-index of 50 and is listed as an inventor on more than 10 patent applications, several of which have been granted. He is a member of ASH, EHA, IMWG, EMN and SITC.
Disclosure information not submitted.
Friday, September 27, 2024
9:00 AM – 10:00 AM East Coast USA Time